Kim, W.R., Loomba, R., Berg, T., Aguilar Schall, R.E., Yee, L.J., Dinh, P.V., et al. (2015) Impact of Longterm Tenofovir Disoproxil Fumarate on Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Oral Antiviral Therapy and HCC Incidence. Cancer, 121, 3631-3638.
https://doi.org/10.1002/cncr.29537

has been cited by the following article:

• TITLE: Chronic Hepatitis B Virus Infection: Biological Parameters in Patients Treated with Tenofovir Disoproxil Fumarate

  AUTHORS: Sanra Déborah Sanogo, Moussa Y. Dicko, Lamine N’Diaye, Ousmane Diarra, Drissa Katilé, Abdoulaye Maiga, Ouatou Mallé, Sabine Drabo, Makan S. Tounkara, Hourouma Sow, Kadiatou Doumbia, Anselme Konaté, Moussa T. Diarra

  KEYWORDS: Viral Hepatitis B, Tenofovir, Biological Parameters

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.14 No.4, April 29, 2024

  ABSTRACT: Chronic hepatitis B causes a liver disease characterized by inflammation of the liver parenchyma. The aim of this study was to investigate the evolution of biological parameters in patients treated with Tenofovir for chronic B infection at the Commune V referral health center in Bamako. We obtained a prevalence of 14.15%. The most represented age group was 31 - 40 years, with 36.8%. The sex ratio was 1.44 in favour of men. Viral load was undetectable after 18 months of treatment in 25 patients (42.37%). Tenofovir, the 1st-line drug in Mali, is effective on the biological parameters monitored in patients.